Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients

Study Overview
=================
Brief Summary
-----------------
In recent months, a new coronavirus, SARS-CoV-2, has been identified as the cause of a serious lung infection named COVID-19 by the World Health Organization. This virus has spread rapidly among the nations of the world and it is the cause of a pandemic and a global health emergency. There is still very little scientific evidence on the virus, however epidemiological data suggest that one of the most frequent comorbidities is diabetes, along with hypertension and heart disease. There is no scientific evidence on the possible effects of this infection on the function of the β cell and on glycemic control. Clinical evidence seems to suggest that COVID-19 infection mostly affects the respiratory system, and an acute worsening of glycemic compensation is not described as generally observed in bacterial pneumonia. However, previous work on acute respiratory syndromes (SARS) caused by similar coronaviruses, had described that the infection has multi-organ involvement related to the expression of the SARS coronavirus receptor, the angiotensin 2 converting enzyme, in different organs, especially at the level of endocrine pancreatic tissue. In the population of this previous work, glucose intolerance and fasting hyperglycaemia have been described and in 37 of 39 diabetic patients examined, a remission of diabetes was observed three years after the infection. It is possible that the coronaviruses responsible for SARS may enter the pancreatic islets using the angiotensin 2 converting enzyme receptor, expressed at the level of the endocrine pancreas, thus causing diabetes. Additionally, previous literature on coronavirus infections (SARS and MERS or Middle-East Respiratory Syndrome) suggested that diabetes could worsen the evolution of the disease. In particular, in case of Middle-East Respiratory Syndrome-CoV infection, diabetic mice had a more prolonged serious illness and a delay in recovery regardless of the viremic titer. This could probably be due to a dysregulation of the immune response, which results in more serious and prolonged lung disease. There are currently no data on pancreatic beta cell function in patients with COVID-19.

Detailed Description
-----------------
The project is monocentric, interventional, non-pharmacological, non-profit. Patients will be enrolled in hospital for confirmed COVID-19 infection (with reverse transcriptase-polymerase chain reaction on the airway swab) but with normal basal blood glucose and no previous history of diabetes or impaired fasting glucose or impaired glucose tolerance. Patients will be compared to a control group of healthy volunteers, not affected by COVID-19 and with no previous history of diabetes or impaired fasting glucose or impaired glucose tolerance. Patients will be also compared with a group of patients with type 2 diabetes but without COVID-19. Once the informed consent has been signed, the clinical parameters and biochemical parameters will be collected according to the time points provided by the protocol in positive COVID-19 patients, in healthy volunteers and in patients with type 2 diabetes. COVID-19 positive patients and healthy controls as well as patients with type 2 diabetes, will undergo a stimulation test of β-cell function (evaluation of the secretive response of insulin to the stimulation test with arginine infusion) and the monitoring of glycemic values through a professional retrospective continuous glucose monitoring. For the test, an infusion solution containing 25% arginine hydrochloride will be used, arginine is an insulinogenic amino acid, useful to verify the possible existence of damage to the cellular beta function induced by COVID-19 infection, clinically observable with changes in insulin secretory response. Given the usefulness of the test, performed for diagnostic purposes, this protocol is identified as non-pharmacological. The test is contraindicated only in patients with severe hepatic and renal insufficiency, in all other subjects the side effects are minimal and spontaneous resolution before the end of the test (flushing 33%, oral paraesthesia 46%, nausea 12%, dizziness 14%). For the stimulation test with arginine infusion, after the basal sampling at (0 minutes), an intravenous injection of arginine 5 grams will be practiced in 60 seconds followed by serial withdrawals at +2, +5, +10 and +30 minutes. The following analytes will be assayed on the basal sample: glycosylated hemoglobin, glycaemia, insulin, pro-insulin, C-peptide, glucagon, serum inflammatory cytokines (Il1β, IL-2, IL-6, IL-7, IL-10, TNF- α, IFN-γ, MIP-1β, MCP-1, GM-CSF, G-CSF Insulin, C-peptide and glucagon will be dosed on all points of the curve.

Official Title
-----------------
Effects of SARS-CoV-2 Infection on Beta-cell Function in Euglycemic Patients

Conditions
-----------------
COVID19, BETA-CELL FUNCTION

Intervention / Treatment
-----------------
* Diagnostic Test: Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria for COVID-19 positive patients Male and female patients with COVID19 and normal basal blood sugar, unprecedented in diabetes or impaired fasting glucose or impaired glucose tolerance Age> 18 years and <80 years Availability to informed consent and corporate privacy Inclusion criteria for healthy subjects Male and female patients not affected by COVID19, unprecedented in diabetes or impaired fasting glucose or impaired glucose tolerance Age> 18 years and <80 years Availability to informed consent and corporate privacy Exclusion criteria for COVID-19 positive patients Age <18 years Previous history of diabetes or impaired fasting glucose or impaired glucose tolerance Severe liver failure Severe kidney failure Exclusion criteria for healthy subjects Age <18 years Previous history of diabetes or impaired fasting glucose or impaired glucose tolerance Positivity to the nasopharyngeal swab for SARS-CoV-2 Severe liver failure Severe kidney failure Inclusion criteria for T2D patients Male and female patients not affected by COVID19 with a diagnosis of type 2 diabetes Age> 18 years and <80 years Availability to informed consent and corporate privacy Exclusion criteria for T2D patients Age <18 years Positivity to the nasopharyngeal swab for SARS-CoV-2 Severe liver failure Severe kidney failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: COVID-19 positive patients<br>Patients will be enrolled in hospital for confirmed COVID-19 infection (with reverse transcriptase-polymerase chain reaction on the airway swab) but with normal basal glucose and no previous history of diabetes or impaired fasting glucose or impaired tolerance glucose. Patients will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient. | Diagnostic Test: Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection<br>* All participants will be subjected to the collection of glycemic data through continuous professional retrospective monitoring of blood glucose for seven days, positioned on the day the test will be performed. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient. The evaluation of insulin secretion will be evaluated by performing the stimulus test with arginine infusion according to validated protocols.<br>* Other names: Positioning of the device for glycemic monitoring;|
| Other: Healthy volunteers<br>Healthy volunteers, not affected by COVID-19 and with no previous history of diabetes or impaired fasting glucose or impaired glucose tolerance will be enrolled. Healthy volunteers will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient. | Diagnostic Test: Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection<br>* All participants will be subjected to the collection of glycemic data through continuous professional retrospective monitoring of blood glucose for seven days, positioned on the day the test will be performed. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient. The evaluation of insulin secretion will be evaluated by performing the stimulus test with arginine infusion according to validated protocols.<br>* Other names: Positioning of the device for glycemic monitoring;|
| Other: Type 2 diabetes patients<br>Patients with established Type 2 diabetes, not affects by COVID-19. Patients will be placed with a professional retrospective glucose monitoring device and will be tested for stimulation with arginine infusion. The device will be placed on the day of the test and will be removed after seven days of recording the glycemic data. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient. | Diagnostic Test: Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection<br>* All participants will be subjected to the collection of glycemic data through continuous professional retrospective monitoring of blood glucose for seven days, positioned on the day the test will be performed. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient. The evaluation of insulin secretion will be evaluated by performing the stimulus test with arginine infusion according to validated protocols.<br>* Other names: Positioning of the device for glycemic monitoring;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum β - cellular function index insulin levels | Difference in insulin levels during and after COVID-19 infection and compared to patients in the control group | all data were collected at Visit 1, 12 months | 
| Serum β - cellular function index C-peptide levels | Difference in C-peptide levels during and after COVID-19 infection and compared to patients in the control group | all data were collected at Visit 1, 12 months | 
| Serum β - cellular function HOMA-β index | Difference in HOMA-β index during and after COVID-19 infection and compared to patients in the control group | all data were collected at Visit 1, 12 months | 
| Serum β - cellular function pro-insulin/insulin ratio | Difference in pro-insulin/insulin ratio during and after COVID-19 infection and compared to patients in the control group | all data were collected at Visit 1, 12 months | 
| Evaluation of the secretory response of insulin to the arginine stimulation test | Check for the existence of damage to the beta cell function induced by COVID-19 infection, clinically observable with changes in the secretory response of insulin | all data were collected at Visit 1, 12 months | 
| Percentage of patients with preserved β cells function | Evidence of impairment of β cell function in the serum of COVID-19 patients | all data were collected at Visit 1, 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose values | Changes in glucose values in COVID-19 patients and healthy volunteers | all data were collected at Visit 1, 12 months | 
| Values of continuous glucose monitoring | Changes in the values of continuous glucose monitoring in both COVID-19 patients and healthy volunteers | all data were collected at Visit 1 and after 7 days, 12 months | 
| Changes in the inflammatory marker interleukin 1-β | Comparison of interleukin 1-β levels in COVID-19 patients compared with healthy subjects | all data were collected at Visit 1, 12 months | 
| Changes in the inflammatory marker interleukin IL-2 | Comparison of interleukin IL-2 levels in COVID-19 patients compared with healthy subjects | all data were collected at Visit 1, 12 months | 
| Changes in the inflammatory marker interleukin IL-6 | Comparison of interleukin IL-6 levels in COVID-19 patients compared with healthy subjects | all data were collected at Visit 1, 12 months | 
| Changes in the inflammatory marker interleukin IL-7 | Comparison of interleukin IL-7 levels in COVID-19 patients compared with healthy subjects | all data were collected at Visit 1, 12 months | 
| Changes in the inflammatory marker interleukin IL-10 | Comparison of interleukin IL-10 levels in COVID-19 patients compared with healthy subjects | all data were collected at Visit 1, 12 months | 
| Changes in the inflammatory marker tumor necrosis factor-α | Comparison of interleukin tumor necrosis factor-α levels in COVID-19 patients compared with healthy subjects | all data were collected at Visit 1, 12 months | 
| Changes in the inflammatory marker interferon gamma | Comparison of interferon gamma levels in COVID-19 patients compared with healthy subjects | all data were collected at Visit 1, 12 months | 
| Changes in the inflammatory marker macrophage inflammatory protein-1β | Comparison of macrophage inflammatory protein-1β levels in COVID-19 patients compared with healthy subjects | all data were collected at Visit 1, 12 months | 
| Changes in the inflammatory marker monocyte chemoattractant protein-1 | Comparison of macrophage inflammatory monocyte chemoattractant protein-1 in COVID-19 patients compared with healthy subjects | all data were collected at Visit 1, 12 months | 
| Changes in the inflammatory marker granulocyte-macrophage colony-stimulating factor | Comparison of macrophage inflammatory granulocyte-macrophage colony-stimulating factor in COVID-19 patients compared with healthy subjects | all data were collected at Visit 1, 12 months | 
| Changes in the inflammatory marker granulocyte colony-stimulating factor | Comparison of macrophage inflammatory granulocyte colony-stimulating factor in COVID-19 patients compared with healthy subjects | all data were collected at Visit 1, 12 months |